Metacognitive Training for Obsessive-Compulsive Disorder: a study protocol for a randomized controlled trial.
Anxiety
Beliefs
Biases
CBT
Group therapy
Metacognitions
Journal
BMC psychiatry
ISSN: 1471-244X
Titre abrégé: BMC Psychiatry
Pays: England
ID NLM: 100968559
Informations de publication
Date de publication:
06 07 2020
06 07 2020
Historique:
received:
04
04
2019
accepted:
04
05
2020
entrez:
8
7
2020
pubmed:
8
7
2020
medline:
22
12
2020
Statut:
epublish
Résumé
A high number of patients with obsessive-compulsive disorder (OCD) do not receive cognitive-behavioral therapy with exposure and response prevention, which is the most effective treatment for OCD. Therefore, Metacognitive Training for OCD (MCT-OCD) was developed, which is a structured group therapy aiming at the modification of dysfunctional (meta-)cognitive biases, beliefs and coping styles. It can be administered by less trained personnel, thus may reach a higher number of patients. An uncontrolled pilot study (MCT-OCD pilot version) provided first evidence that the training is highly accepted by patients; OC symptoms decreased with a high effect size (η Eighty patients with OCD will be recruited. After a blinded assessment at baseline (-t1), patients will be randomly assigned either to the intervention group (MCT-OCD; n = 40) or to a care as usual control group (n = 40). The MCT-OCD aims to enhance patients' metacognitive competence in eight modules by addressing dysfunctional (meta-)cognitive biases and beliefs associated with OCD (e.g., intolerance of uncertainty). After 8 weeks, patients will be invited to a post assessment (t1), and then they will receive a follow-up online questionnaire 3 months following t1 (t2). The primary outcome is the Y-BOCS total score, and the secondary outcomes include the HDRS, OCI-R, OBQ-44, MCQ-30, WHOQOL-BREF, BDI-II, and subjective appraisal ratings of the MCT-OCD. We expect that OC symptoms will decrease more in the intervention group compared with the care as usual control group from -t1 to t1 and that treatment gains will be maintained until t2. The planned study is the first to investigate the MCT-OCD, a promising new treatment, in a randomized controlled trial. The MCT-OCD may help to overcome existing treatment barriers for patients with OCD. German Registry for Clinical Studies ( DRKS00013539 ), 22.02.2018.
Sections du résumé
BACKGROUND
A high number of patients with obsessive-compulsive disorder (OCD) do not receive cognitive-behavioral therapy with exposure and response prevention, which is the most effective treatment for OCD. Therefore, Metacognitive Training for OCD (MCT-OCD) was developed, which is a structured group therapy aiming at the modification of dysfunctional (meta-)cognitive biases, beliefs and coping styles. It can be administered by less trained personnel, thus may reach a higher number of patients. An uncontrolled pilot study (MCT-OCD pilot version) provided first evidence that the training is highly accepted by patients; OC symptoms decreased with a high effect size (η
METHODS
Eighty patients with OCD will be recruited. After a blinded assessment at baseline (-t1), patients will be randomly assigned either to the intervention group (MCT-OCD; n = 40) or to a care as usual control group (n = 40). The MCT-OCD aims to enhance patients' metacognitive competence in eight modules by addressing dysfunctional (meta-)cognitive biases and beliefs associated with OCD (e.g., intolerance of uncertainty). After 8 weeks, patients will be invited to a post assessment (t1), and then they will receive a follow-up online questionnaire 3 months following t1 (t2). The primary outcome is the Y-BOCS total score, and the secondary outcomes include the HDRS, OCI-R, OBQ-44, MCQ-30, WHOQOL-BREF, BDI-II, and subjective appraisal ratings of the MCT-OCD. We expect that OC symptoms will decrease more in the intervention group compared with the care as usual control group from -t1 to t1 and that treatment gains will be maintained until t2.
DISCUSSION
The planned study is the first to investigate the MCT-OCD, a promising new treatment, in a randomized controlled trial. The MCT-OCD may help to overcome existing treatment barriers for patients with OCD.
TRIAL REGISTRATION
German Registry for Clinical Studies ( DRKS00013539 ), 22.02.2018.
Identifiants
pubmed: 32631261
doi: 10.1186/s12888-020-02648-3
pii: 10.1186/s12888-020-02648-3
pmc: PMC7336399
doi:
Banques de données
DRKS
['DRKS00013539']
Types de publication
Clinical Trial Protocol
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
350Références
J Affect Disord. 2016 Oct;203:241-247
pubmed: 27310102
Behav Res Ther. 2004 Apr;42(4):385-96
pubmed: 14998733
World Psychiatry. 2016 Feb;15(1):80-1
pubmed: 26833615
Behav Res Ther. 2007 Sep;45(9):2232-40
pubmed: 17306222
Psychiatry Res. 2011 Aug 30;189(1):1-9
pubmed: 21276619
Depress Anxiety. 2011 Jul;28(7):574-81
pubmed: 21681869
Cogn Behav Ther. 2005;34(3):140-7
pubmed: 16195053
Acta Psychiatr Scand. 2009 Feb;119(2):98-106
pubmed: 18822090
Biol Psychol. 2016 Dec;121(Pt B):221-232
pubmed: 26594019
Int J Methods Psychiatr Res. 2012 Sep;21(3):169-84
pubmed: 22865617
Compr Psychiatry. 2005 Nov-Dec;46(6):453-9
pubmed: 16275213
J Anxiety Disord. 2018 May;56:17-25
pubmed: 29656823
J Affect Disord. 2011 Jan;128(1-2):175-7
pubmed: 20696481
J Clin Epidemiol. 2007 Dec;60(12):1234-8
pubmed: 17998077
Lancet Psychiatry. 2016 Aug;3(8):730-739
pubmed: 27318812
J Behav Ther Exp Psychiatry. 2008 Jun;39(2):117-32
pubmed: 17418090
Psychother Res. 2020 Apr;30(4):474-486
pubmed: 31072282
J Clin Psychiatry. 1998;59 Suppl 20:22-33;quiz 34-57
pubmed: 9881538
Psychother Psychosom. 2016;85(4):231-4
pubmed: 27230865
Nervenarzt. 2007 Jun;78(6):651-6
pubmed: 16832698
Behav Res Ther. 2007 Oct;45(10):2257-67
pubmed: 17521605
Behav Res Ther. 1997 Jul;35(7):667-81
pubmed: 9193129
Dialogues Clin Neurosci. 2010;12(2):209-20
pubmed: 20623925
J Clin Psychiatry. 2013 Jul;74(7):685-90
pubmed: 23945445
J Consult Clin Psychol. 1973 Feb;40(1):69-77
pubmed: 4569703
Behav Res Ther. 2003 Aug;41(8):863-78
pubmed: 12880642
Behav Res Ther. 2015 Feb;65:5-10
pubmed: 25544403
J Anxiety Disord. 2007;21(3):394-406
pubmed: 16814981
Behav Res Ther. 2009 Apr;47(4):301-7
pubmed: 19203749
J Affect Disord. 2017 Oct 15;221:17-24
pubmed: 28628763
Arch Gen Psychiatry. 1989 Nov;46(11):1006-11
pubmed: 2684084
Behav Res Ther. 2001 Aug;39(8):987-1006
pubmed: 11480839
Clin Psychol Rev. 2015 Aug;40:156-69
pubmed: 26117062
Psychol Assess. 2002 Dec;14(4):485-96
pubmed: 12501574
Schizophr Res. 2018 Nov;201:20-26
pubmed: 29903626
Qual Life Res. 2004 Mar;13(2):299-310
pubmed: 15085902
Behav Ther. 2011 Sep;42(3):399-412
pubmed: 21658523
Clin Psychol Psychother. 2019 Mar;26(2):227-240
pubmed: 30456821
Cogn Behav Ther. 2019 Mar;48(2):89-105
pubmed: 30088441
Behav Ther. 2019 Jan;50(1):165-176
pubmed: 30661557
Acta Psychiatr Scand. 2011 May;123(5):387-97
pubmed: 20946200
J Anxiety Disord. 2008 May;22(4):734-49
pubmed: 17913454
J Behav Ther Exp Psychiatry. 2008 Dec;39(4):451-8
pubmed: 18295186
J Psychol. 2017 Aug 18;151(6):532-546
pubmed: 29077549
Psychiatry Res. 2017 Dec;258:24-36
pubmed: 28982038
J Neurol Neurosurg Psychiatry. 1960 Feb;23:56-62
pubmed: 14399272
J Anxiety Disord. 2006;20(8):1016-35
pubmed: 16621437
Worldviews Evid Based Nurs. 2018 Apr;15(2):130-139
pubmed: 29489070
Soc Sci Med. 1998 Jun;46(12):1569-85
pubmed: 9672396
Psychother Psychosom Med Psychol. 2007 Sep-Oct;57(9-10):395-404
pubmed: 17590836
Behav Res Ther. 2005 Nov;43(11):1527-42
pubmed: 16299894
Front Psychol. 2018 Dec 10;9:2551
pubmed: 30618972
J Anxiety Disord. 2016 Mar;38:79-87
pubmed: 26851748
Clin Psychol Rev. 2008 Dec;28(8):1310-25
pubmed: 18701199
Int J Psychiatry Clin Pract. 2018 Mar;22(1):40-46
pubmed: 28691550
Behav Res Ther. 1985;23(5):571-83
pubmed: 4051930
Psychol Bull. 1986 Jan;99(1):20-35
pubmed: 2871574
Cogn Behav Ther. 2019 Mar;48(2):162-176
pubmed: 30064295
Behav Res Methods. 2007 May;39(2):175-91
pubmed: 17695343
Schizophr Bull. 2016 Jul;42(4):952-62
pubmed: 26748396
J Consult Clin Psychol. 1996 Jun;64(3):532-9
pubmed: 8698947
Cogn Behav Ther. 2018 May;47(3):229-245
pubmed: 28681684
BMC Psychiatry. 2011 Dec 20;11:200
pubmed: 22185596
J Anxiety Disord. 2016 May;40:8-17
pubmed: 27061971